We are excited to announce an opportunity for a motivated PhD student to join our team at the DIAMET group. We currently have a fully funded PhD position available, and we are seeking a candidate who is eager to contribute to our research projects, with a particular focus on signaling metabolites and their role in the pathophysiology of obesity-related comorbidities. Additionally, we are interested in investigating the circadian rhythm and extracellular vesicles.
ABOUT OUR GROUP:
The Diabetes and Metabolic Associated Diseases Research Group (DIAMET, www.diamet.org) led by Dr. Sonia Fernandez-Veledo (Biochemist) and Dr. Joan Vendrell (endocrinologist), is a dynamic and multidisciplinary translational research group located at the Hospital Universitary Joan XXIII (Tarragona, Spain). Our main objective is to study metabolic derangements associated with obesity, such as diabetes, NAFLD, and cardiovascular disease. The DIAMET group belongs to IISPV-URV, and is part of the CIBERDEM network of excellence (ISCIII). It also includes two consolidated research groups recognized by the Agency for Management of University Research Grants of the Generalitat de Catalunya (2021 SGR 01409, SGR 21/829).
WHAT WE OFFER:
As the selected candidate, you will have the opportunity to gain valuable experience by working with conditional knockout mice and other in vivo models, as well as various types of cell cultures. You will also acquire strong knowledge and experience in biochemistry, molecular and cellular biology through the application of different techniques. Notably, we are also work with patients and well phenotypic clinical cohorts.
REQUIREMENTS OF THE IDEAL CANDIDATE:
If you are interested in this exciting opportunity, please send your curriculum vitae, university certificates, academic record, and two letters of recommendation (if possible) to:
Email subject: Candidate for Predoctoral-DIAMET (call 2023)
Follow us at @DiametT
(1) Marsal-Beltran, A. et al. 2023. Succinate/SUCNR1 axis as a protective mechanism of injured hepatocytes in NAFLD. Metabolism: Clinical and Experimental (2) Villanueva-Carmona, T. et al. 2023. SUCNR1 signaling in adipocytes controls energy metabolism by modulating circadian clock and leptin expression. Cell Metabolism. (3) Huber-Ruano, I. et al. 2022. Orally administered Odoribacter laneus improves glucose control and inflammatory profile in obese mice by depleting circulating succinate. Microbiome. (4) Osuna-Prieto, F.J. et al.. 2021. Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults. Cardiovascular Diabetology. (5) Astiarraga, B. et al. 2020. Impaired Succinate Response to a Mixed Meal in Obesity and Type 2 Diabetes Is Normalized After Metabolic Surgery. Diabetes Care. (6) Ceperuelo-Mallafré, V. et al. 2019. Pre- operative circulating succinate levels as a biomarker for diabetes remission after bariatric surgery. Diabetes Care. (7) Keiran, N. et al. SUCNR1 signaling controls macrophage alternative activation and regulates immune metabolic responses in obesity. Nature Immunology (8) Serena, C. et al., 2018. Elevated circulating levels of succinate in human obesity are linked to specific gut microbiota. The ISME journal.
For additional information candidates can send an email at: firstname.lastname@example.org